InvestMoat
Healthcare | Biologics + PipelineDupixent + Eylea HDEylea Biosimilar Pressure

Regeneron Pharmaceuticals, Inc.

REGN~$81B capAnalysed Sep 25

Hold

Hold for Long-Term Compounding

72
MoatMoat narrowing over 5–10 years76
Growth68
Val71
0255075100

Combined average of Moat (AI Resilience), Growth, and Valuation scores.

76/100

Regeneron's moat is anchored by Dupixent (partnered with Sanofi, with exclusivity extending through the early 2030s) and the Eylea HD next-generation franchise, supported by proprietary protein-engineering platforms (VelociSuite) and decades of clinical trial data. The original Eylea 2mg is facing imminent biosimilar entry — Samsung's biosimilar is precluded from US launch until January 2027 — but Eylea HD is converting patients ahead of biosimilar competition.

Regeneron's competitive position rests on regulatory exclusivity (Dupixent + Eylea HD), proprietary discovery platforms (VelociSuite, VelocImmune), and immuno-oncology pipeline depth — partially offset by Eylea 2mg biosimilar exposure:

  • Dupixent: The Atopic-Disease Powerhouse: Dupixent (partnered 50/50 with Sanofi for global commercialization) treats atopic dermatitis, asthma, eosinophilic esophagitis, prurigo nodularis, and (most recently) COPD. Global Dupixent sales are running at ~$15B+ annually with 20%+ growth, and patent exclusivity extends into the early 2030s in major markets. Regeneron books its share through the Sanofi collaboration revenue line. New indications (chronic spontaneous urticaria, bullous pemphigoid) extend the franchise runway.
  • Eylea HD: Out-Running the Biosimilar: Regeneron is aggressively converting Eylea 2mg patients to Eylea HD (8mg, longer dosing interval), which has independent patent protection extending into the late 2030s. Eylea HD US revenue jumped 52% to $468M in Q1 2026; the just-resolved Samsung biosimilar litigation precludes Samsung's US launch until January 2027, giving Regeneron extra time to convert the franchise. Combined US Eylea + Eylea HD net sales fell 10% to $941M in Q1 — the conversion math is the central thesis.
  • VelociSuite: A Reproducible Discovery Engine: VelocImmune (humanized mice for fully human antibody discovery) and VelociMab/Mouse have produced a high-yield pipeline including Dupixent, Praluent, Libtayo, Linvoseltamab, and the linvoseltamab BCMA bispecific. Newer bispecifics targeting CD3 + tumor-associated antigens give Regeneron a credible immuno-oncology franchise alongside its mature inflammation/ophthalmology businesses.
  • Capital Allocation Discipline: Regeneron repurchased $803M of stock in Q1 2026 and authorized an additional $3B buyback in April 2026. Founder-led management (Schleifer/Yancopoulos) has a 30+ year track record of disciplined R&D allocation and conservative capital structure. The dividend was initiated in 2024 — modest but a signal of capital-return maturity.

Regeneron's moat structure is led by regulatoryLockIn (Dupixent + Eylea HD), proprietaryData (Regeneron Genetics Center exome dataset), businessLogic (VelocImmune platform), and talentScarcity (Yancopoulos-led discovery team). These moats are highly AI-resilient — AI does not disrupt patent-protected biologics; it actually accelerates Regeneron's pipeline targeting through computational protein engineering and patient stratification on the Genetics Center dataset. The structural risks are pipeline-execution risk (itepekimab, bispecifics) and the Eylea 2mg biosimilar transition, neither of which is AI-driven.

81.8 resilient · 65.0 vulnerable · 80/20 = 78.4 · = 78 · blended with 72 projected = 76

Open a moat to read its note.

AI-Vulnerable Moats2 intact · 3 N/A
AI-Resilient Moats2 strong · 2 intact · 3 N/A

Regulatory lock-in is the one pillar likely to step down. Dupixent's US compound patent ends in March 2031, and Sanofi has said it does not expect to offset the sales impact, while Eylea HD and the bispecific approvals keep enough protection for the pillar to land at intact. The Genetics Center exome dataset and the VelocImmune platform hold, because a biosimilar copies a molecule, not the discovery engine. The Eylea 2mg biosimilar transition has already started and is a status and growth matter, not a trend.

78 today → 72 if the trend completes · scored 76 (70/30)

Is Regeneron Pharmaceuticals stock a buy?

We rate Regeneron Pharmaceuticals Hold, with a composite score of 72/100: moat 76, growth 68 and valuation 71. The valuation score is struck against our bear, base and bull targets and moves with the price.

What is Regeneron Pharmaceuticals' moat?

Regeneron Pharmaceuticals scores 76/100 on moat. Regeneron's moat is anchored by Dupixent (partnered with Sanofi, with exclusivity extending through the early 2030s) and the Eylea HD next-generation franchise, supported by proprietary protein-engineering platforms (VelociSuite) and decades of clinical trial data.

How fast is Regeneron Pharmaceuticals expected to grow?

We estimate 8-12% a year over the next three to five years, for a growth score of 68/100.

What is Regeneron Pharmaceuticals' price target?

Our base case is $880, with $520 in the bear case and $1,150 in the bull case.